Shire plc recently announced its Xiidra™ (lifitegrast ophthalmic solution) 5% is now available by prescription in the United States.
Xiidra is a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, and was granted U.S. Food and Drug Administration (FDA) approval on July 11, 2016.
Shire has also launched two patient-focused resources to share information about prescription coverage and savings. Xiidra iinsider is an optional program that allows patients to sign up to receive information and special offers via text or email, and ask iiris is a phone service with live-person responses to questions about insurance coverage, benefits, co-pays and pharmacy availability.
Click here to read the full press release.